Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront <scp> <i>DPYD</i> </scp> Genotyping-Reference-Cited by-同舟云学术

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping

Published:2022-06-12 Issue:4 Volume:112 Page:791-802
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

White Cassandra¹²^ORCID,Scott Rodney J.²³⁴,Paul Christine¹²,Ziolkowski Andrew⁴,Mossman David⁴,Fox Stephen B.⁵⁶,Michael Michael⁵⁶,Ackland Stephen¹²⁷^ORCID

Affiliation:

1. School of Medicine and Public Health University of Newcastle, College of Health, Medicine and Wellbeing Callaghan New South Wales Australia

2. Hunter Medical Research Institute New Lambton Heights New South Wales Australia

3. School of Biomedical Science and Pharmacy University of Newcastle, College of Health, Medicine and Wellbeing Callaghan New South Wales Australia

4. Department of Molecular Genetics Pathology North John Hunter Hospital New Lambton Heights New South Wales Australia

5. Peter MacCallum Cancer Centre Melbourne Victoria Australia

6. Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Victoria Australia

7. Hunter Cancer Centre Lake Macquarie Private Hospital Gateshead New South Wales Australia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2667

Reference82 articles.

1. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

2. Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

3. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

4. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of diagnostic markers and molecular clusters of cuproptosis-related genes in alcohol-related liver disease based on machine learning and experimental validation;Heliyon;2024-09

2. Current development of molecular classifications of gastric cancer based on omics (Review);International Journal of Oncology;2024-08-01

3. Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study;Pharmaceutics;2024-07-19

4. Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia;Internal Medicine Journal;2024-07-04

5. Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists;Internal Medicine Journal;2024-05-20